secwatch.observer — SEC 8-K summary
======================================

Issuer:     AtriCure, Inc. (ATRC)
CIK:        0001323885
Form:       8-K
Filed at:   2023-11-01T23:59:59+00:00
Accession:  0001323885-23-000107
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AtriCure Q3 revenue $98.3M (+18% YoY); positive adjusted EBITDA $4.7M
---------------------------------------------------------------------

- Worldwide revenue $98.3M, up 18.1% YoY; U.S. $81.7M (+17.1%), International $16.6M (+23.2%).
- Net loss of $9.1M, improved $3.2M YoY; GAAP EPS loss $0.20, same as adjusted.
- Positive adjusted EBITDA of $4.7M vs. negative $0.7M in Q3 2022, an improvement of $5.4M.
- FY2023 revenue guidance $394M-$396M (19-20% growth); adjusted EBITDA $18M-$20M.
- Gross margin 75.2%, up 110 bps YoY, driven by operational efficiencies and production leverage.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1323885/000132388523000107/0001323885-23-000107-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1323885/000132388523000107/atrc-20231101.htm
  HTML page:      https://secwatch.observer/filing/0001323885-23-000107

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer